138 related articles for article (PubMed ID: 16080536)
1. Hypoxia alters cathepsin B / inhibitor profiles in oral carcinoma cell lines.
Wickramasinghe NS; Banerjee K; Nagaraj NS; Vigneswaran N; Zacharias W
Anticancer Res; 2005; 25(4):2841-9. PubMed ID: 16080536
[TBL] [Abstract][Full Text] [Related]
2. Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer.
Krepela E; Procházka J; Kárová B; Cermák J; Roubková H
Neoplasma; 1998; 45(5):318-31. PubMed ID: 9921922
[TBL] [Abstract][Full Text] [Related]
3. Differential localization of cysteine protease inhibitors and a target cysteine protease, cathepsin B, by immuno-confocal microscopy.
Calkins CC; Sameni M; Koblinski J; Sloane BF; Moin K
J Histochem Cytochem; 1998 Jun; 46(6):745-51. PubMed ID: 9603786
[TBL] [Abstract][Full Text] [Related]
4. Expression of cysteine proteinases cathepsins B and K and of cysteine proteinase inhibitor cystatin C in giant cell tumor of tendon sheath.
Hansen T; Petrow PK; Gaumann A; Keyszer GM; Otto M; Kirkpatrick CJ; Kriegsmann J
Mod Pathol; 2001 Apr; 14(4):318-24. PubMed ID: 11301348
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines.
Heidtmann HH; Salge U; Abrahamson M; Bencina M; Kastelic L; Kopitar-Jerala N; Turk V; Lah TT
Clin Exp Metastasis; 1997 Jul; 15(4):368-81. PubMed ID: 9219725
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin B activity in human lung tumor cell lines: ultrastructural localization, pH sensitivity, and inhibitor status at the cellular level.
Spiess E; Brüning A; Gack S; Ulbricht B; Spring H; Trefz G; Ebert W
J Histochem Cytochem; 1994 Jul; 42(7):917-29. PubMed ID: 8014475
[TBL] [Abstract][Full Text] [Related]
7. Modulation of invasive properties of murine squamous carcinoma cells by heterologous expression of cathepsin B and cystatin C.
Coulibaly S; Schwihla H; Abrahamson M; Albini A; Cerni C; Clark JL; Ng KM; Katunuma N; Schlappack O; Glössl J; Mach L
Int J Cancer; 1999 Nov; 83(4):526-31. PubMed ID: 10508490
[TBL] [Abstract][Full Text] [Related]
8. Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation.
Corticchiato O; Cajot JF; Abrahamson M; Chan SJ; Keppler D; Sordat B
Int J Cancer; 1992 Oct; 52(4):645-52. PubMed ID: 1399147
[TBL] [Abstract][Full Text] [Related]
9. Distribution, activity and concentration of cathepsin B and cystatin C in the wall of aortic aneurysm.
Gacko M; Chyczewski L; Chrostek L
Pol J Pathol; 1999; 50(2):83-6. PubMed ID: 10481531
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of cystatin M during the progression of oropharyngeal squamous cell carcinoma from primary tumor to metastasis.
Vigneswaran N; Wu J; Zacharias W
Oral Oncol; 2003 Sep; 39(6):559-68. PubMed ID: 12798398
[TBL] [Abstract][Full Text] [Related]
11. Cysteine cathepsins B and L and their inhibitors stefins A and B in carcinoma of the oropharynx: immunohistochemical study.
Strojan P; Oblak I; Gale N; Smid L; Kos J
Histopathology; 2008 Nov; 53(5):612-4. PubMed ID: 18983473
[No Abstract] [Full Text] [Related]
12. Latency of cathepsin B secreted by human colon carcinoma cells is not linked to secretion of cystatin C and is relieved by neutrophil elastase.
Keppler D; Waridel P; Abrahamson M; Bachmann D; Berdoz J; Sordat B
Biochim Biophys Acta; 1994 May; 1226(2):117-25. PubMed ID: 8204657
[TBL] [Abstract][Full Text] [Related]
13. Grafting of features of cystatins C or B into the N-terminal region or second binding loop of cystatin A (stefin A) substantially enhances inhibition of cysteine proteinases.
Pavlova A; Björk I
Biochemistry; 2003 Sep; 42(38):11326-33. PubMed ID: 14503883
[TBL] [Abstract][Full Text] [Related]
14. Decreased activity of cathepsins L + B and decreased invasive ability of PC3 prostate cancer cells.
Colella R; Casey SF
Biotech Histochem; 2003 Apr; 78(2):101-8. PubMed ID: 14533846
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma.
Budihna M; Strojan P; Smid L; Skrk J; Vrhovec I; Zupevc A; Rudolf Z; Zargi M; Krasovec M; Svetic B; Kopitar-Jerala N; Kos J
Biol Chem Hoppe Seyler; 1996 Jun; 377(6):385-90. PubMed ID: 8839984
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the interaction of valine-10 in cystatin C with the S2 subsite of cathepsin B.
Lindahl P; Ripoll D; Abrahamson M; Mort JS; Storer AC
Biochemistry; 1994 Apr; 33(14):4384-92. PubMed ID: 8155656
[TBL] [Abstract][Full Text] [Related]
17. Differential susceptibility of metastatic and primary oral cancer cells to TRAIL-induced apoptosis.
Vigneswaran N; Wu J; Nagaraj N; Adler-Storthz K; Zacharias W
Int J Oncol; 2005 Jan; 26(1):103-12. PubMed ID: 15586230
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning and characterization of cystatin, a cysteine protease inhibitor, from bufo melanostictus.
Liu W; Ji S; Zhang AM; Han Q; Feng Y; Song Y
Biosci Biotechnol Biochem; 2013; 77(10):2077-81. PubMed ID: 24096668
[TBL] [Abstract][Full Text] [Related]
19. Silencing of cystatin M in metastatic oral cancer cell line MDA-686Ln by siRNA increases cysteine proteinases and legumain activities, cell proliferation and in vitro invasion.
Vigneswaran N; Wu J; Nagaraj N; James R; Zeeuwen P; Zacharias W
Life Sci; 2006 Jan; 78(8):898-907. PubMed ID: 16150465
[TBL] [Abstract][Full Text] [Related]
20. Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy.
Rinne R; Saukko P; Järvinen M; Lehesjoki AE
Ann Med; 2002; 34(5):380-5. PubMed ID: 12452481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
